MND in the News

Study identifies protein important for motor coordination and exercise performance
Study identifies protein important for motor coordination and exercise performance

Researchers at Karolinska Institutet in Sweden have identified a protein that improves muscular metabolism, motor…Read More

Print Friendly, PDF & Email
SPTLC1 gene variants in Juvenile Amyotrophic Lateral Sclerosis

This study aimed to identify the genetic variants associated with juvenile ALS. The data broadened…Read More

Print Friendly, PDF & Email
Clene Phase 2 Trial Testing in RESCUE-ALS Study

Topline data is expected in the next couple of months for the Clene’s Phase 2…Read More

Print Friendly, PDF & Email
Subtle Changes in MicroRNA-218 May Fuel MND

Dropping the levels of microRNA-218 (miR-218) — a small molecule that regulates the activity of…Read More

Print Friendly, PDF & Email
Trial of WVE-004 in Patients With C9orf72 Mutations Begins Dosing

Dosing has begun in a clinical trial of WVE-004, Wave Life Sciences‘ investigational therapy for amyotrophic lateral…Read More

Print Friendly, PDF & Email
A Knowledge-Based Machine Learning Approach to Gene Prioritisation in ALS/MND

Several rare disruptive gene variants have been associated with ALS and are responsible for about…Read More

Print Friendly, PDF & Email
Estimated Prevalence and Incidence of Amyotrophic Lateral Sclerosis and SOD1 and C9orf72 Genetic Variants

This study estimated the number of prevalent and incident ALS cases overall and superoxide dismutase…Read More

Print Friendly, PDF & Email
Newly discovered genetic mutations may increase risk for ALS

University of Utah Health researchers have detected a set of genetic mutations that appear to…Read More

Print Friendly, PDF & Email
Scientists discover a new genetic form of ALS in children

An international team of researchers led by scientists at the National Institutes of Health and…Read More

Print Friendly, PDF & Email
ORPHAZYME Announces Topline Data from Phase 3 Trial in ALS

Orphazyme, a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of…Read More

Print Friendly, PDF & Email
Update on Tofersen, for SOD1-ALS

Biogen have announced a Two-Part Tofersen Access Program. Beginning in mid-July 2021, after patients in…Read More

Print Friendly, PDF & Email
Mitochondrial associated ER membrane (MAM) compartment and its dysregulation in Amyotrophic lateral sclerosis (ALS)

    This review discusses the structural and functional relevance of MAMs in ALS and…Read More

Print Friendly, PDF & Email
Is phrenic nerve motor responses an option to SVC in clinical trials for ALS?

Respiratory tests are fundamental for monitoring respiratory function in ALS, and essential in clinical trials.…Read More

Print Friendly, PDF & Email
Phase 2 Randomised, Double-Blind, Placebo-Controlled Study of Oral Dimethyl Fumarate in ALS (TEALS Study)

Neuroinflammation is an important pathogenic mechanism in amyotrophic lateral sclerosis (ALS), with regulatory T cells…Read More

Print Friendly, PDF & Email
Should routine genetic testing be considered for all cases of MND?

Researchers from the University of Sheffield as part of the AMBRoSIA biobank, have found higher…Read More

Print Friendly, PDF & Email
Mitochondrial bioenergetic deficits in C9orf72 amyotrophic lateral sclerosis motor neurons cause dysfunctional axonal homeostasis l University of Edinburgh

Dr Arpan Mehta alongside Dr Bhuvaneish Selvaraj and Professor Siddharthan Chandranat Euan MacDonald Centre for…Read More

Print Friendly, PDF & Email
Scientists identify genetic variation linked to severity of ALS | EurekAlert!

Researchers at Wake Forest School of Medicine found that ALS patients with a genetic variation…Read More

Print Friendly, PDF & Email
Amyotrophic Lateral Sclerosis: Developing Drugs for Treatment Guidance for Industry | FDA

The FDA recently released a new guidance document to assist sponsors in the clinical development…Read More

Print Friendly, PDF & Email
Kadimastem Announces Promising Interim Results of Cohort A of Its Phase 1/2a Clinical Trial in ALS | BioSpace

Kadimastem Ltd., a clinical stage cell therapy company, announced promising interim results of its Phase…Read More

Print Friendly, PDF & Email
Print Friendly, PDF & Email